Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
Abstract Background Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challen...
Những tác giả chính: | , , , , , , , , |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
BMC
2024-01-01
|
Loạt: | Journal of Translational Medicine |
Những chủ đề: | |
Truy cập trực tuyến: | https://doi.org/10.1186/s12967-023-04779-z |